Last reviewed · How we verify

NCT04473742: MacFibOsis

Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

Completed NA Last updated 4 January 2022
What this trial tests

NA trial testing Blood collection in History of Exposure to Silica or Asbestosis in 23 participants. Completed in 15 December 2021.

Timeline
31 March 2021
Primary endpoint
15 December 2021
15 December 2021

Quick facts

Lead sponsorRennes University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment23
Start date31 March 2021
Primary completion15 December 2021
Estimated completion15 December 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Rennes University Hospital

Who can join

18 and older, any sex, with History of Exposure to Silica or Asbestosis or Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MDM from healthy donors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood collection

Trials testing the same drug.

Other Rennes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04473742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing